Corrections

Novel drugs and drug combinations for treating tuberculosis

BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g6563 (Published 03 November 2014) Cite this as: BMJ 2014;349:g6563

The original version of this Therapeutics article (BMJ 2014;349:g5948, doi:10.1136/bmj.g5948) advised that “Hypoalbuminaemia was a risk factor for QT interval prolongation, and delamanid should not be used if the serum albumin concentration is above 2.8 g/dL.” The recommendation for delamanid’s use was incorrect and should have read, “Hypoalbuminaemia was a risk factor for QT interval prolongation, and delamanid should not be used if the serum albumin concentration is below 2.8 g/dL.” This error has now been corrected in the online version of the article.

Notes

Cite this as: BMJ 2014;349:g6563

View Abstract